PBS access to ibrutinib expanded to Mantle Cell Lymphoma

Ibrutinib (Imbruvica) has been listed on the PBS from August 1 for relapsed or refractory mantle cell lymphoma (MCL). The listing expands reimbursed access to the Bruton’s tyrosine kinase inhibitor beyond refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). It will also spare patients the high cost of $134,000 per year for a ...

Already a member?

Login to keep reading.

© 2021 the limbic